Page 100 - 南京医科大学学报自然科学版
P. 100
第43卷第2期
·242 · 南 京 医 科 大 学 学 报 2023年2月
失。但这也从侧面佐证,艾立布林引起的神经毒 lin mesylate reduces tumor microenvironment abnormali⁃
性、疲劳等不良反应对患者生活质量的影响较轻 ty by vascular remodeling in preclinical human breast
微。此外,现有的前瞻性研究表明长程治疗(> 3个 cancer models[J].Cancer Sci,2014,105(10):1334-1342
月)与艾立布林诱导的较重神经病变显著相关。此 [9] SACHDEV P,RONEN R,DUTKOWSKI J,et al. System⁃
atic analysis of genetic and pathway determinants of erib⁃
研究的中位随访时间尚短(5 个月),可能影响了艾
ulin sensitivity across 100 human cancer cell lines from
立布林神经毒性实际发生率的统计 [16-17] 。此外,艾
the cancer cell line encyclopedia(CCLE)[J]. Cancers,
立布林在大部分前瞻性研究中均表现出 OS 的获
2022,14(18):4532
益 [10-11,13] ,而本研究由于随访时长的限制,未能获得
[10] CORTES J,O'SHAUGHNESSY J,LOESCH D,et al. Erib⁃
成熟的OS数据,后续随访的延长将进一步扩充与完 ulin monotherapy versus treatment of physician's choice
善艾立布林在中国HER2阴性晚期乳腺癌患者中的 in patients with metastatic breast cancer(EMBRACE):a
疗效与安全性数据。 phase 3 open⁃label randomised study[J]. Lancet,2011,
综上,对于紫杉类及蒽环类药物经治的 HER2 377(9769):914-923
阴性晚期乳腺癌患者,艾立布林是一种安全有效的 [11] KAUFMAN P A,AWADA A,TWELVES C,et al. Phase
新型化疗药物。在前线使用时,艾立布林治疗 Ⅲ open⁃label randomized study of eribulin mesylate ver⁃
HER2阴性晚期乳腺癌患者展现出更好的治疗获益, sus capecitabine in patients with locally advanced or met⁃
astatic breast cancer previously treated with an anthracy⁃
同时,以艾立布林为基础的联合方案安全性良好,且
cline and a taxane[J]. J Clin Oncol,2015,33(6):594-601
较艾立布林单药更能延长患者的PFS,为HER2阴性
[12] TWELVES C,AWADA A,CORTES J,et al. Subgroup
晚期乳腺癌患者提供了一种新型联合方案。
analyses from a phase 3,open⁃label,randomized study of
[参考文献] eribulin mesylate versus capecitabine in pretreated pa⁃
[1] 邱海波,曹素梅,徐瑞华. 基于2020年全球流行病学数 tients with advanced or metastatic breast cancer[J].
据分析中国癌症发病率、死亡率和负担的时间趋势及 Breast Cancer⁃Basic,2016,10:77-84
[13] WU Y,WANG Q,ZHANG J,et al. Incidence of peripher⁃
与美国和英国数据的比较[J]. 癌症,2022,41(4):165-
al neuropathy associated with eribulin mesylate versus
177
vinorelbine in patients with metastatic breast cancer:sub⁃
[2] SIEGEL R L,MILLER K D,FUCHS H E,et al. Cancer
group analysis of a randomized phase Ⅲ study[J]. Sup⁃
Statistics,2021[J]. CA Cancer J Clin,2021,71(1):7-33
port Care Cancer,2020,28(8):3819⁃3829
[3] ARCIERO C A,GUO Y,JIANG R,et al. ER(+)/HER2
[14] 楼伊慧,孙 晋,李天女. 正电子显像剂在乳腺癌诊疗
(+)breast cancer has different metastatic patterns and
中的应用进展[J]. 南京医科大学学报(自然科学版),
better survival than ER(⁃)/HER2(+)breast cancer[J].
Clin Breast Cancer,2019,19(4):236-45 2021,41(9):1411-1415
[15] 柏柳安宁,夏结来,王 陵,等. 真实世界研究中的常见
[4] OGIYA R,SAGARA Y,NIIKURA N,et al. Impact of sub⁃
type on survival of young patients with stage IV breast 偏倚及其控制[J]. 中国临床药理学与治疗学,2020,25
cancer[J]. Clin Breast Cancer,2019,19(3):200-207. (12):1422-1428
[5] National Comprehensive Cancer Network. NCCN clinical [16] ZHAO B,ZHAO H,ZHAO J. Incidence and clinical pa⁃
practice guidelines in oncology:breast cancer,version rameters associated with eribulin mesylate ⁃ induced pe⁃
ripheral neuropathy[J]. Crit Rev Oncol Hemat,2018,
2.2022[Z]. 2022
[6] PEREIRA R B,EVDOKIMOV N M,LEFRANC F,et al. 128:110-117
Marine⁃derived anticancer agents:clinical benefits,inno⁃ [17] TSURUTANI J,SAKATA Y,MATSUOKA T. Chemother⁃
vative mechanisms,and new targets[J].Mar Drugs,2019, apy⁃induced peripheral neuropathy in breast cancer pa⁃
17(6):329 tients treated with eribulin:interim data from a post⁃mar⁃
[7] WAN M C,QIN W,LEI C,et al. Biomaterials from the keting observational study[J]. Breast Cancer,2019,26
sea:future building blocks for biomedical applications (2):235-243
[J]. Bioact Mater,2021,6(12):4255-4285 [收稿日期] 2022-09-27
[8] FUNAHASHI Y,OKAMOTO K,ADACHI Y,et al. Eribu⁃ (本文编辑:唐 震)